arrow
H

Hans Salwender

asklepios klinik altona and asklepios klinik st. georg
H指数:46
被引数:8,771

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

作者更正: 基于Teclistamab的诱导治疗符合移植条件的新诊断多发性骨髓瘤: 2期试验

2026-07-060
OAAI
Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial

基于Teclistamab的诱导治疗可移植的新诊断多发性骨髓瘤: 一项2期试验

2026-06-250
OAAI
Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma—A Multicenter Analysis

探索后BCMA/GPRC5D时代治疗格局:在五药耐药多发性骨髓瘤患者序贯免疫疗法失败后,Selinexor、Bortezomib和Dexamethasone的疗效——一项多中心分析

2026-03-310
OAAI
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial

IgG或IgA多发性骨髓瘤患者中Hevylite检测的预后影响:GMMG-MM5试验结果

2025-11-010
OAAI
Prospective systematic classification of causes of death in the course of multiple myeloma

多发性骨髓瘤病程中死亡原因的前瞻性系统分类

2025-10-200
OA
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

基于EMN–HARMONY联盟平台的机器学习风险分层策略用于多发性骨髓瘤:见解

2025-10-090
OAAI
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study

维奈克拉或安慰剂联合硼替佐米和地塞米松治疗复发或难治性多发性骨髓瘤(BELLINI):一项随机、III期研究的最终总生存结果

2025-06-270
PRE
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)

来那度胺联合利妥昔单抗、地塞米松、高剂量阿糖胞苷(ARA-C)和顺铂作为难治性或复发性侵袭性B细胞非霍奇金淋巴瘤的挽救治疗——一项开放标签、多中心I/II期研究(DSHNHL-R6)。

2025-04-150
OA
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
2024-12-030
OAAI
Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
2024-11-200
OAAI
Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial

新诊断多发性骨髓瘤患者长期随访分析:基于GMMG骨髓瘤登记系统,在随机III期GMMG-HD6试验后的无进展生存期和总生存期研究

BLOOD
IF23.1
2024-11-050
PRE
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma

伊萨图昔单抗联合卡非佐米,来那度胺和地塞米松治疗高危新诊断多发性骨髓瘤患者的通俗语言总结

2024-09-300
OAAI
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study
LEUKEMIA
IF13.4
2024-06-030
OAAI
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
LEUKEMIA
IF13.4
2023-12-078
OAAI
Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study
2023-11-094
OAAI
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
2023-03-072
OAAI
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

多发性骨髓瘤患者骨髓与外周血异常浆细胞NGF检测的比较分析

2023-01-270
OAAI